EU panel supports approval of Anoro, Incruse for treatment of COPD

02/21/2014 | Reuters · Medscape (free registration)

The European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed the approval of Anoro, a combination of vilanterol and umeclidinium, as a treatment for chronic obstructive pulmonary disease. The drug was jointly developed by GlaxoSmithKline and Theravance. The committee also recommended the approval of umeclidinium, sold under the brand name Incruse, as a monotherapy for COPD.

View Full Article in:

Reuters · Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT